Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


DesignMedix Inc.

This article was originally published in Start Up

Executive Summary

One of the key ways pathogens survive in patients receiving drug therapy for infection is by physically ridding their cells of the chemicals through molecular mechanisms known as efflux pumps. Given this role, biopharma researchers have been investigating compounds meant to act as efflux pump inhibitors and so increase the efficacy of existing antibacterial and other drugs. Count DesignMedix LLC. in that group. The start-up thinks its approach will eventually give rise to drugs that reverse resistance to fluoroquinolone antibiotics like Cipro, but the company is first working on a potential anti-malarial compound.

You may also be interested in...

MGB Biopharma Ltd.

MGB Biopharma Ltd. believes it may be able to create compounds that directly kill bacteria before they ever have a chance to mutate. Its plan is to develop chemicals that bind to bacterial DNA and stop transcription of key genes. Indeed, the fi rst three letters of the company’s name stand for minor groove binders, because this is the class of drug that management aspires to develop as antibacterials.

Kenta Biotech Ltd.

Kenta Biotech Ltd., is betting that fully human monoclonal antibodies will become valuable treatments for hospitalized patients battling serious bacterial infections. Some strong clinical data is giving Kenta confidence. It recently reported positive results from a Phase IIa clinical trial of critically ill patients with hospital-acquired and ventilator-acquired pneumonia caused by pseudomonas aeruginosa. All those who completed the three-infusion course of Kenta’s lead candidate survived and fully cleared their pneumonia. No negative systemic or infusion-site responses were reported.

As Drug-Resistant Microbes Rise, Antibiotic Start-Ups Need Savvy Investors

VCs see rich exit opportunities, especially for start-ups with multiple products in their pipelines. In this issue we profile four emerging antibiotic drug developers: Cempra Pharmaceuticals, DesignMedix, Kenta Biotech and MGB Biopharma.

Related Content


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts